111 results
Primary objectives:* To investigate the safety of multiple dosages of E4;* To investigate the efficacy of multiple dosages of E4 on hormone levels related to prostate function.Secondary objectives:* To investigate the pharmacodynamic effects of E4…
This study is designed in order to determine the type and timing of sexual rehabilitation after prostate cancer treatment according to the patient*s and the patient*s partner*s point of view. Furthermore, it will assess which health care provider…
The objectives are to determine generic, cancer-generic and prostate cancer-specific HRQOL and costs outside the hospital in CRPC patients during treatment (including best supportive care, docetaxel, cabazitaxel, abiraterone and enzalutamide) in…
The main goal of this phase II study is to investigate whether a focal ablative SBRT boost to the macroscopic tumor is feasible and associated with acceptable toxicity in addition to whole gland prostate SBRT. Based on the present study, a phase III…
The main objective is to evaluate the safety and tolerability of Ad[I/PPT-E1A] as an adjuvant treatment for localised prostate cancer before radical prostatectomy. A secondary objective is to explore the histopathological and immunological effects…
Am2: Primary Objective* To compare the Overall Survival (OS) benefit of docetaxel and prednisone with and without lenalidomide as first-line combination therapy in chemo-naïve metastatic CRPC Secondary Objectives* Progression-Free Survival (PFS), *…
To determine the exposure and clearance of intravenous docetaxel in patients with castration-resistant prostate cancer and non-castration-resistant prostate cancer. All samples will be measured with a validated LC-MS/MS method
The primary objective for this trial is to assess the local cancer control achieved with FLA in patients with localized low to intermediate risk prostate cancer (Gleason 3+3, 3+4 or Gleason 4+3).Secondary objectives are to determine effectiveness of…
The objective of this study is to compare the overall survival of patients with prostate cancer who are no longer responding to hormone therapy (castration resistant) and who have not yet received chemotherapy live longer (overall survival) when…
PrimaryTo assess the safety and tolerability of olaparib when given in addition to abiraterone and torecommend, by assessment of dose-limiting toxicities and other safety and tolerability data, adose of olaparib for further study when given in…
To evaluate the safety, efficacy and to acquire data on patient experience of minimally invasive, percutaneous, image guided IRE for the ablation of prostate cancer.
The purpose of this study is to evaluate the efficacy and safety of MDV3100, a novel potent androgen-receptor antagonist without known agonist activity, in asymptomatic or mildly symptomatic patients with progressive metastatic prostate cancer who…
1. To assess the effects of 3 months neoadjuvant androgen ablation with enzalutamide on the surgicial margin status of men with non-metastasized prostate cancer.2. To properly evaluate the effects of androgen ablation on gene expression, analyses of…
In this research project it is investigated if abdominal ultrasound measurement of prostate volume performed by the GP is equivalent to the prostate volume measured by the transrectal ultrasound (TRUS) performed by the urologist. Also the effect on…
The objective of the study is to dimplement and evaluate a new care path for elderly prostate cancer patients with complex care needs within 20 months. This will be done withinthe department of urology at the Meander Medisch Centrum at Amersfoort,…
The primary objective is to study whether treatment with the mTOR inhibitor Everolimus results in an objectable change in phosphorylation of the selected downstream effectors 4eBP1 and p70S6K in human prostate cancer biopsies. A secondary objective…
Primary objective:- To evaluate the pharmacokinetics, metabolism, and excretion of MDV3100 in plasma, urine, and feces after a single oral 160 mg (100 µCi) dose of 14C-MDV3100.Secondary objective:- To evaluate safety and tolerability of a single…
-To answer the main question *Can we demonstrate a decreased prevalence of fatigue (i.e. a lower score on the fatigue assessment) in patients in complete remission after successful treatment of a gynaecological malignancy, after treatment of a…
To compare the effect of paclitaxel plus MORAb-003 to paclitaxel plus placebo on progression free survival (PFS) as determined by RECIST in subjects who are in a first platinum-resistant or refractory relapse of ovarian cancer.
The aim of this study is to develop and evaluate a shared care survivorship care plan (SCP) to follow-up patients with metastatic testicular cancer after completion of chemotherapy that resulted in complete remission.